Intangible Benefits Are Influential In OTC Switch Decisions – CDER’s Ganley
This article was originally published in The Tan Sheet
Executive Summary
Non-measurable benefits can tip the scales in the benefit/risk consideration of an OTC switch NDA, suggests Charles Ganley, director of CDER's Office of Drug Evaluation IV. One way to look at non-measurable benefits is how OTC ingredients "lower the threshold” for patient “misery” prior to seeking relief, he says.
You may also be interested in...
OTC Antiseptic Wash Industry Disputes FDA Cost Estimate For Proposed 'Rub' Monograph
FDA’s estimate for the economic impact of its proposal requiring additional safety and efficacy data for OTC antiseptic rub excludes the current benefit the products provide in fighting infection, says the American Cleaning Institute. Industry places annual cost over a 10-year-period at as much as $6.7m.
OTC Antiseptic Wash Industry Disputes FDA Cost Estimate For Proposed 'Rub' Monograph
FDA’s estimate for the economic impact of its proposal requiring additional safety and efficacy data for OTC antiseptic rub excludes the current benefit the products provide in fighting infection, says the American Cleaning Institute. Industry places annual cost over a 10-year-period at as much as $6.7m.
CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations
A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.